Lp-PLA2: Evolution of a Biomarker

Pharmaceutical companies are increasingly experimenting with biomarkers in order to improve results of their clinical trials. Diagnostics companies are ideally suited to help, but pharma tends to shun them and diagnostics companies perceive that when both sides work together, the diagnostics side has less leverage. Here's how diaDexus believes it can retain clout as it works with GSK on a promising new diagnostic and therapeutic target: Lp-PLA2 for cardiovascular disease.